Roquefort Therapeutics plc (LON:ROQ)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1.100
+0.150 (15.79%)
Mar 5, 2026, 10:34 AM GMT
Market Cap1.56M -50.2%
Revenue (ttm)n/a
Net Income-882.45K
EPS-0.01
Shares Out163.73M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume957,662
Average Volume1,089,774
Open0.970
Previous Close0.950
Day's Range0.900 - 1.100
52-Week Range0.900 - 3.000
Beta-0.49
RSI39.55
Earnings DateApr 27, 2026

About Roquefort Therapeutics

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in v... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 7
Stock Exchange London Stock Exchange
Ticker Symbol ROQ
Full Company Profile

Financial Performance

Financial Statements